In a stunning legal decision, a New York judge has ruled that evidence does not support state terrorism charges against Luigi Mangione, accused of the ambush killing of UnitedHealthcare CEO Brian Thompson.
In a dramatic courtroom ruling, a judge has dismissed terrorism charges against Luigi Mangione in the murder case of UnitedHealthcare CEO Brian Thompson, while maintaining second-degree murder charges. Supporters rally as legal battles unfold.
In a surprising courtroom decision, Luigi Mangione had his first-degree and second-degree murder charges dismissed, though he still faces other serious charges in the high-profile case involving United HealthCare executive Brian Thompson's death.
In a surprising turn of events, a New York judge has dismissed two terrorism charges against Luigi Mangione, accused of murdering UnitedHealthcare CEO Brian Thompson. The judge allowed the second-degree murder charge to stand, stating insufficient evidence for terrorism allegations.
Stocks showed mixed results as the market pauses after record highs. UnitedHealth's gains boost the Dow, while inflation concerns weigh on the S&P 500 and Nasdaq. What’s next for investors?
In a surprising move, Warren Buffett's Berkshire Hathaway invests $1.6 billion in UnitedHealth Group, a stock down 40% this year. Can this gamble pay off amid turmoil?
As U.S. stocks ended the week with mixed results, the Michigan Consumer Sentiment Index revealed a drop in economic confidence. UnitedHealth saw a surge after Berkshire Hathaway increased its stake, while Sunrun soared on strong earnings. Get the full market recap!
U.S. equities experienced a mixed performance at midday, with retail sales showing strong consumer spending. While the Dow slightly rose, the S&P 500 and Nasdaq fell, driven by varying performances from major stocks including UnitedHealth and Salesforce.
S&P 500 futures are nearly flat after a record close, while UnitedHealth jumps over 9% thanks to investments from Buffett and Burry. What's next for the market as economic indicators loom?
UnitedHealth Group's stock continues to decline as the insurer battles rising medical costs and a challenging earnings outlook. Following the abrupt CEO change, the company anticipates no earnings growth until 2026.
